Allogenic human umbilical cord derived mesenchymal stem cell (Tianjin Tasly)

人脐带间充质干细胞（天士力）

Report date: 2025/12/05 20:00:50

Base Information

Drug NameAllogenic human umbilical cord derived mesenchymal stem cell (Tianjin Tasly)

Drug Alias NameB2278B-2278

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsHeart FailureCardiomyopathies

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesTianjin Tasly Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTianjin Tasly Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsHeart FailureCardiomyopathies

Inactive IndicationsN/A

Other Information

ATC CodeN/A